New drug combo shows promise for rare blood cancer
NCT ID NCT04763616
First seen May 04, 2026 · Last updated May 17, 2026 · Updated 1 time
Summary
This study tested a combination of two drugs, isatuximab and cemiplimab, in 37 adults with a rare blood cancer called NK/T-cell lymphoma that had come back or stopped responding to prior treatment. The goal was to see if the combination could shrink tumors and improve outcomes. The approach uses the drugs to boost the immune system's ability to attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NATURAL KILLER/T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Kangnamgu, 06351, South Korea
Conditions
Explore the condition pages connected to this study.